Nine Novel Growth Hormone Receptor Gene Mutations in Patients with Laron Syndrome1
Author(s) -
MarieLaure Sobrier,
Florence Dastot,
Philippe Duquesnoy,
Nurgün Kandemir,
N Yordam,
Michel Goossens,
Serge Amselem
Publication year - 1997
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jcem.82.2.3725
Subject(s) - growth hormone receptor , frameshift mutation , missense mutation , endocrinology , growth hormone binding protein , medicine , receptor , mutation , nonsense mutation , biology , cytokine receptor , gene , extracellular , genetics , hormone , growth hormone
The GH receptor (GHR) is a member of the cytokine receptor superfamily; GH binding protein is the solubilized extracellular domain of the GHR. Abnormalities in the GHR produce an autosomal recessive form of GH resistance, the Laron syndrome, characterized by growth failure and the clinical appearance of severe GH deficiency despite elevated circulating GH levels. In 13 unrelated patients with undetectable levels of GH binding protein, we characterized nine novel mutations in the GHR gene. These molecular defects comprise three nonsense mutations (Q65X, W80X, and W157X), one frameshift (36delC), two splice defects (G-->A at 70 + 1, C-->T at 723), and three missense mutations (C38S, S40L, and W50R) located in the extracellular domain of the receptor, and thus would be expected to interfere with GH binding activity. These results further confirm the broad heterogeneity of mutations underlying this rare GH resistance syndrome.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom